Skip to Main Content

There’s a wave of new cancer drugs being developed, approved, and covered in China, many of them targeting genetic drivers of a patient’s tumor.

They’re the same types of drugs that have transformed the way cancer is now treated in American patients — and that have made U.S. drug makers billions.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.